Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Appian Corporation announced its financial results for Q2 2026, showing 19% year-over-year total revenue growth to $203.3 million driven by increased cloud subscriptions and professional services. The company improved its GAAP operating loss compared to the prior year and recorded a significant increase in non-GAAP operating income and adjusted EBI…
Lifetime Brands, Inc. announced its financial results for Q2 2026, reporting net sales growth of 7.4% year-over-year and significant earnings improvement driven by a $40.1 million tariff refund. The company repaid $40 million in term debt, showed robust growth in warehouse club and e-commerce channels, and reaffirmed net sales guidance while raisin…
Tarsus Pharmaceuticals announced robust second quarter 2026 financial results driven by 69% year-over-year growth in net product sales of their FDA-approved eye drop XDEMVY for Demodex blepharitis. The company increased its full-year sales guidance and advanced its pipeline with the pending acquisition of Alkeus Pharmaceuticals, adding a Phase 3 cl…
Ocugen provided a business update detailing FDA clearance to initiate its Phase 3 trial for OCU410 on geographic atrophy, received RMAT designation, secured a licensing agreement for OCU400 in the Middle East and North Africa, and closed a $130 million convertible senior notes financing. They remain on track for key data readouts in 2027 for their …
Tarsus Pharmaceuticals announced a $125 million private investment in public equity (PIPE) financing alongside its pending acquisition of Alkeus Pharmaceuticals. The financing garnered participation from existing and new institutional investors, supporting Tarsus' plans to advance clinical development and commercial activities primarily in ophthalm…
Tarsus Pharmaceuticals announced its definitive agreement to acquire Alkeus Pharmaceuticals, a private biotech focused on retinal diseases, for approximately $450 million upfront plus potential milestones and royalties. The acquisition adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational drug targeting Stargardt disease—a sig…
Safe Pro Group Inc., a Nasdaq-listed developer of AI-enabled defense and security solutions, announced a $780,000 purchase order from a new Department of War Prime Contractor. The order includes edge AI threat detection technology and Blue UAS drones, with work starting in Q3 2026 and expected completion in Q1 2027. This award marks the fifth recen…
Iovance Biotherapeutics reported a record second quarter 2026 revenue of approximately $99 million, a 66% year-over-year increase, driven primarily by strong demand for its commercial product Amtagvi in the U.S. The company improved its gross margin to 56% and is reviewing its full-year 2026 revenue guidance upwards. Clinical progress includes FDA …
Gilat Satellite Networks announced a successful demonstration of its breakthrough AI-based interference detection and cancellation technology for satellite links. This patent-pending solution significantly improves interference mitigation by up to 10 times compared to conventional methods, maintaining signal integrity even under challenging interfe…
Resolute Holdings Management, Inc. reported second-quarter fiscal 2026 financial results showing a net loss per share of $1.53 under GAAP, primarily impacted by consolidation of GPGI Holdings. However, non-GAAP fee-related earnings per share increased significantly to $0.69, driven by new and expanded management agreements. The company repurchased …
Capital City Bank Group, Inc. has been recognized for the 15th consecutive year on Florida Trend's annual "Best Companies to Work For in Florida" list, rising to No. 8 in the large company category in 2026. This accolade highlights the bank's commitment to a supportive and empowering workplace. Additional recognitions include Forbes ranking the ban…
Commerce.com, Inc. announced its Q2 2026 financial results, posting total revenue of $84.5 million, a slight increase YoY, and a 14% growth in Gross Merchandise Volume. For the second consecutive quarter, the company reported positive GAAP net income of $1.1 million and improved non-GAAP operating income and adjusted EBITDA. Investments continue in…
GH Research PLC reported financial results for Q2 2026, highlighting successful completion of Phase 1 trials and FDA alignment on CMC and device plans for their Phase 3 pivotal program targeting treatment-resistant depression (TRD). The company strengthened its US and EU patent portfolio for mebufotenin therapies, published positive Phase 2a postpa…
Lee Enterprises, a digital-first local news and advertising platform, announced strong preliminary Q3 fiscal 2026 results, including $5 million net income and a 23% year-over-year increase in Adjusted EBITDA. Digital revenue now constitutes 57% of total revenue, reflecting successful digital transformation. The company increased its fiscal 2026 Adj…
Tilray Brands, Inc. announced the launch of the Mollo Lite Blackberry Lemon Seltzers 4-Pack, introducing its first light THC beverage multi-pack in Canada. This low-dose, sessionable cannabis beverage format targets adult consumers seeking approachable potency with refreshing flavor and convenient multi-pack options. The product enhances Tilray's l…
Gogo Inc., a leading provider of broadband connectivity solutions for business and military aviation markets, announced Q2 2026 results with total revenue of $222.8 million, a 1% decrease year-over-year. Military/government service revenue grew 40% year-over-year and 20% sequentially, marking a record quarter. Net loss was $2.0 million with adjuste…
Harrow, Inc. announced the acquisition of TYRVAYA®, a novel nasal spray treatment for dry eye disease, from Viatris Inc., aiming to enhance its ophthalmic product portfolio. TYRVAYA offers an alternative to eye drops with a unique delivery method and complements Harrow's existing products, expanding treatment options for dry eye sufferers. The acqu…
CareCloud, Inc. announced its Q2 2026 financial results showing 16% revenue growth to $31.9 million and sustained profitability with a GAAP net income of $1.1 million. The company expanded its product portfolio by acquiring Empower Healthcare & Compliance Partners, entering the compliance and audit-defense market. CareCloud reaffirmed its full-year…
GPGI, Inc. announced its Q2 2026 financial results, showing a 4% decrease in pro forma adjusted net sales to $473.2 million and a 13% decline in pro forma adjusted EBITDA to $113.9 million, with margins down 230 basis points. Notably, CompoSecure delivered record performance driven by ROS-enabled improvements, while Husky met expectations amid mark…
The Macerich Company announced its operating partnership's intent to offer $600 million in exchangeable senior notes due 2031 through a private placement targeting qualified institutional buyers. The notes offer semi-annual interest and will be guaranteed by Macerich on a senior unsecured basis. Proceeds will be used to refinance existing secured d…
Ligand Pharmaceuticals reported robust second quarter 2026 financial results with a 32% year-over-year growth in royalty revenue, raising the low end of its adjusted EPS guidance while maintaining revenue guidance. The company completed a $700 million zero-interest convertible debt financing and finalized the acquisition of XOMA Royalty, significan…
Generate Biomedicines Inc. reported continued progress in its clinical programs and platform advancements during Q2 2026. The company is advancing its Phase 3 SOLAIRIA studies for GB-0895 in severe asthma, enrolling patients globally, and will present Phase 1b data for GB-0895 in COPD at the ERS Congress. It also dosed the first cohort in a Phase 1…
Monte Rosa Therapeutics announced robust Q2 2026 results featuring significant clinical and development milestones, including completed enrollment in a key MRT-8102 study targeting cardiovascular disease risk, activation of multiple Phase 2 trials across inflammatory and oncology programs, and a strong financial position with $626 million in cash t…
Avalo Therapeutics reported second quarter 2026 financial results highlighting positive topline Phase 2 results for its lead drug candidate, abdakibart, in hidradenitis suppurativa (HS). The company plans to initiate a registrational Phase 3 clinical program in the first half of 2027 and has expanded its pipeline with AVTX-010, a next-generation an…
Cullinan Therapeutics provided an update on its clinical programs advancing T cell engagers for autoimmune diseases and cancer, highlighting upcoming multi-dose regimen data for CLN-978 and velinotamig, progression to Phase 2 studies in 2027, and a potentially registrational Phase 2 trial for CLN-049 in relapsed/refractory AML starting Q3 2026. The…
